
China Growth Capital is an early-stage venture capital firm that invests in companies from seed to Series B across fintech, enterprise technology, consumer internet, frontier technology, and life science sectors. The firm focuses on identifying mega trends in these areas, believing that enterprise and technology represent the next phase of economic growth in China.
Their most common stage is series-c (43% of deals). Average disclosed round size is $807.6M (across 6 rounds with reported amounts).
Portfolio
7
Fund Size
$10B
Top Stage
Series C
Last 12 Mo
0
Portfolio Breakdown
Stage Distribution
Sector Distribution
Investment Activity
DealsAvg Round Size
Portfolio
7 investments
| Company | Round | Amount | Date |
|---|---|---|---|
| Series C | — | Jan 2022 | |
| IInxMed | Series A | $19M | Sep 2020 |
| Series C | $125M | Jan 2019 | |
| Series C | $50M | Sep 2018 | |
| Series B | $4.5B | Apr 2016 | |
| IImpraise | Seed | $1.6M | Apr 2016 |
| Growth | $150M | — |
Top Co-Investors
Palm Drive Capital1 shared
henQ1 shared
CCB Trust1 shared
China Life1 shared
Primavera Capital1 shared
SoftBank Ventures Asia1 shared
JAFCO Asia1 shared
K2VC1 shared
Matrix Partners1 shared
Morningside Ventures1 shared
Yunqi Partners1 shared
Matrix Partners China1 shared
GIC1 shared
BlackRock1 shared
Sequoia Capital1 shared
Last updated: 8 March 2026